Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F24%3A00587672" target="_blank" >RIV/67985823:_____/24:00587672 - isvavai.cz</a>

Alternative codes found

RIV/00023001:_____/24:00084948 RIV/00216208:11110/24:10481628 RIV/00216208:11120/24:43927288 RIV/60461373:22330/24:43929096 RIV/00064165:_____/24:10481628

Result on the web

<a href="https://doi.org/10.1186/s12933-024-02298-9" target="_blank" >https://doi.org/10.1186/s12933-024-02298-9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s12933-024-02298-9" target="_blank" >10.1186/s12933-024-02298-9</a>

Result language

angličtina

Original language name

Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure

Original language description

BackgroundSodium-glucose cotransporter 2 inhibitors (SGLT-2i) are glucose-lowering agents used for the treatment of type 2 diabetes mellitus, which also improve heart failure and decrease the risk of cardiovascular complications. Epicardial adipose tissue (EAT) dysfunction was suggested to contribute to the development of heart failure. We aimed to elucidate a possible role of changes in EAT metabolic and inflammatory profile in the beneficial cardioprotective effects of SGLT-2i in subjects with severe heart failure.Methods26 subjects with severe heart failure, with reduced ejection fraction, treated with SGLT-2i versus 26 subjects without treatment, matched for age (54.0 +/- 2.1 vs. 55.3 +/- 2.1 years, n.s.), body mass index (27.8 +/- 0.9 vs. 28.8 +/- 1.0 kg/m2, n.s.) and left ventricular ejection fraction (20.7 +/- 0.5 vs. 23.2 +/- 1.7%, n.s.), who were scheduled for heart transplantation or mechanical support implantation, were included in the study. A complex metabolomic and gene expression analysis of EAT obtained during surgery was performed.ResultsSGLT-2i ameliorated inflammation, as evidenced by the improved gene expression profile of pro-inflammatory genes in adipose tissue and decreased infiltration of immune cells into EAT. Enrichment of ether lipids with oleic acid noted on metabolomic analysis suggests a reduced disposition to ferroptosis, potentially further contributing to decreased oxidative stress in EAT of SGLT-2i treated subjects.ConclusionsOur results show decreased inflammation in EAT of patients with severe heart failure treated by SGLT-2i, as compared to patients with heart failure without this therapy. Modulation of EAT inflammatory and metabolic status could represent a novel mechanism behind SGLT-2i-associated cardioprotective effects in patients with heart failure.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Cardiovascular Diabetology

ISSN

1475-2840

e-ISSN

1475-2840

Volume of the periodical

23

Issue of the periodical within the volume

1

Country of publishing house

GB - UNITED KINGDOM

Number of pages

17

Pages from-to

223

UT code for WoS article

001258675500003

EID of the result in the Scopus database

2-s2.0-85197112388